These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 18339206)

  • 1. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).
    Pillai SK; Wong JK; Barbour JD
    Retrovirology; 2008 Mar; 5():26. PubMed ID: 18339206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
    Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
    J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
    Binka M; Ooms M; Steward M; Simon V
    J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Wang X; York IA; Zheng YH
    J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.
    Fourati S; Malet I; Binka M; Boukobza S; Wirden M; Sayon S; Simon A; Katlama C; Simon V; Calvez V; Marcelin AG
    AIDS; 2010 Sep; 24(15):2313-21. PubMed ID: 20729708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
    Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
    J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
    Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
    Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F.
    Albin JS; Anderson JS; Johnson JR; Harjes E; Matsuo H; Krogan NJ; Harris RS
    J Mol Biol; 2013 Apr; 425(7):1172-82. PubMed ID: 23318957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.
    Iwabu Y; Kinomoto M; Tatsumi M; Fujita H; Shimura M; Tanaka Y; Ishizaka Y; Nolan D; Mallal S; Sata T; Tokunaga K
    J Biol Chem; 2010 Nov; 285(46):35350-8. PubMed ID: 20833716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
    Albin JS; Brown WL; Harris RS
    Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.
    Izumi T; Shirakawa K; Takaori-Kondo A
    Mini Rev Med Chem; 2008 Mar; 8(3):231-8. PubMed ID: 18336343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
    Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
    Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    Han Y; Wang X; Dang Y; Zheng YH
    PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
    Fan B; Cen S; Jiang JD
    Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.